CA2906501A1 - Sequestrants of advanced glycation end product (age) precursors - Google Patents

Sequestrants of advanced glycation end product (age) precursors Download PDF

Info

Publication number
CA2906501A1
CA2906501A1 CA2906501A CA2906501A CA2906501A1 CA 2906501 A1 CA2906501 A1 CA 2906501A1 CA 2906501 A CA2906501 A CA 2906501A CA 2906501 A CA2906501 A CA 2906501A CA 2906501 A1 CA2906501 A1 CA 2906501A1
Authority
CA
Canada
Prior art keywords
alkyl
pharmaceutical composition
composition according
cycloalkyl
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2906501A
Other languages
English (en)
French (fr)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus BESEV
Robert J. Miller
Andrew T. Papoulis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA2906501A1 publication Critical patent/CA2906501A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CA2906501A 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors Abandoned CA2906501A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
US61/792,719 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
CA2906501A1 true CA2906501A1 (en) 2014-09-25

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906501A Abandoned CA2906501A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Country Status (24)

Country Link
US (2) US20160024233A1 (https=)
EP (1) EP2968403A1 (https=)
JP (4) JP2016512830A (https=)
KR (1) KR20150130492A (https=)
CN (1) CN105188718A (https=)
AR (1) AR095593A1 (https=)
AU (2) AU2014235500A1 (https=)
BR (1) BR112015023404A8 (https=)
CA (1) CA2906501A1 (https=)
CL (1) CL2015002624A1 (https=)
CR (1) CR20150545A (https=)
DO (1) DOP2015000221A (https=)
EA (1) EA201591733A1 (https=)
HK (1) HK1220607A1 (https=)
IL (1) IL241406A0 (https=)
MA (1) MA38487A1 (https=)
MX (1) MX2015012843A (https=)
PE (1) PE20151766A1 (https=)
PH (1) PH12015502019A1 (https=)
SG (2) SG10201707590XA (https=)
TN (1) TN2015000390A1 (https=)
TW (1) TW201521744A (https=)
UY (1) UY35441A (https=)
WO (1) WO2014150873A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CN111405870A (zh) * 2017-08-31 2020-07-10 西托索尔本茨公司 从体液中降低晚期糖基化终末产物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
AU2005214971A1 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
WO2011106542A2 (en) * 2010-02-24 2011-09-01 Relypsa, Inc. Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
IL241406A0 (en) 2015-11-30
KR20150130492A (ko) 2015-11-23
EP2968403A1 (en) 2016-01-20
WO2014150873A1 (en) 2014-09-25
JP2016512830A (ja) 2016-05-09
SG10201707590XA (en) 2017-11-29
US20180265613A1 (en) 2018-09-20
PE20151766A1 (es) 2015-12-11
PH12015502019A1 (en) 2016-01-11
EA201591733A1 (ru) 2016-01-29
US20160024233A1 (en) 2016-01-28
JP2018135365A (ja) 2018-08-30
MA38487A1 (fr) 2017-12-29
BR112015023404A8 (pt) 2019-12-03
TW201521744A (zh) 2015-06-16
JP2022037143A (ja) 2022-03-08
DOP2015000221A (es) 2015-12-15
MX2015012843A (es) 2016-08-08
UY35441A (es) 2014-10-31
CR20150545A (es) 2015-12-01
BR112015023404A2 (pt) 2017-07-18
HK1220607A1 (zh) 2017-05-12
AR095593A1 (es) 2015-10-28
TN2015000390A1 (en) 2017-01-03
CL2015002624A1 (es) 2016-03-11
JP2020055850A (ja) 2020-04-09
CN105188718A (zh) 2015-12-23
AU2019201259A1 (en) 2019-03-14
SG11201506413PA (en) 2015-09-29
AU2014235500A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CN102858817B (zh) 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
AU729205B2 (en) Cationic polymers as toxin-binding agents
CA2831392A1 (en) Conjugated lipomers and uses thereof
CN101448875A (zh) 鬼臼毒素类的高分子量结合体
JP7436576B2 (ja) ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
JP2022037143A (ja) 終末糖化産物（ａｇｅ）前駆体の捕捉剤
CN108026271B (zh) 6配位铂络合物的高分子偶联物
US20100093973A1 (en) Poly(amino acid) compound having inhibitory activity on absorption of phosphorus and phosphorus absorption inhibitor
JP2017526767A (ja) 主鎖ポリアミン
OA17560A (en) Sequestrants of advanced glycation end product (AGE) precursors.
JP7088476B2 (ja) インドール及びその誘導体吸着剤
JP6429399B2 (ja) 抗プリオン化合物のマレイン酸塩及びその製造方法、並びにその医薬組成物
CN120398706A (zh) 具有组织黏附和ros响应性能的共聚物、载药纳米粒及其制备方法和应用
US10946028B2 (en) Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex
WO2025122826A1 (en) Hyaluronic acid-nonsteroidal anti-inflammatory drug conjugates for treating inflammation-mediated pathologies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190219

FZDE Discontinued

Effective date: 20210913